Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2024


Joint Venture Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2024

Publication date
March 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition
4 - fully revised and updated

Joint Venture Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Fully revised and updated, the report provides details of joint venture deals from 2016 to 2024.

The report provides access to joint venture deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals.

Chapter 4 provides a review of the leading joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

Chapter 6 provides a comprehensive and detailed review of joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the joint venture deal.

The deal directory includes a comprehensive listing of all joint venture deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in joint venture dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about joint venture alliances.


Key benefits

Joint Venture Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse joint venture deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Joint Venture Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading biopharma companies worldwide.

Joint Venture Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in joint venture dealmaking in the biopharma industry
  • Overview of joint venture deal structure
  • Directory of joint venture deal records covering pharmaceutical and biotechnology
  • The leading joint venture deals by value
  • Most active joint venture dealmakers
  • The leading joint venture partnering resources


In Joint Venture Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type


Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Joint Venture Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for joint venture deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Joint Venture Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse joint venture deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in joint venture dealmaking

2.1. Introduction

2.2. Definition of joint venture deal

2.3. Trends in joint venture deals since 2016

2.3.1. Joint venture dealmaking by year, 2016-2024

2.3.2. Joint venture dealmaking by phase of development, 2016-2024

2.3.3. Joint venture dealmaking by industry sector, 2016-2024

2.3.4. Joint venture dealmaking by therapy area, 2016-2024

2.3.5. Joint venture dealmaking by technology type, 2016-2024

2.3.6. Joint venture dealmaking by most active company, 2016-2024

2.4. Reasons for entering into joint venture partnering deals

2.5. The future of joint venture deals


Chapter 3 – Overview of joint venture deal structure

3.1. Introduction

3.2. Joint venture agreement structure


Chapter 4 – Leading joint venture deals

4.1. Introduction

4.2. Top joint venture deals by value


Chapter 5 – Top 25 most active joint venture dealmakers

5.1. Introduction

5.2. Top 25 most active joint venture dealmakers


Chapter 6 – Joint venture deals including contracts directory

6.1. Introduction

6.2. Joint venture deals with contracts 2016-2024


Deal directory

Deal directory – joint venture dealmaking by companies A-Z

Deal directory – joint venture dealmaking by therapy area

Deal directory – joint venture dealmaking by technology type


About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering



Figure 1: Definition of joint venture deal

Figure 2: Trends in joint venture deal announcements, 2016-2024

Figure 3: Joint venture deals signed at each phase of development, 2016-2024

Figure 4: Joint venture deals by industry sector, 2016-2024

Figure 5: Joint venture deals by therapy area, 2016-2024

Figure 6: Joint venture deals by technology type, 2016-2024

Figure 7: Top 25 most active joint venture dealmakers, 2016-2024

Figure 8: Top joint venture deals by value, 2016-2024

Figure 9: Most active joint venture dealmakers, 2016-2024

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3 Rivers Biotech, 3E Bioventures Capital, 3SBio, 1717 Life Science Ventures, A*STAR’ Institute of Molecular and Cell Biology, A2A Pharmaceuticals, AAP Implantate AG, Abilita Bio, ABVC BioPharma, Accumulus Synergy, Aceso Life Science, Acnos Pharma, ACT Genomics, Adalvo, ADC Therapeutics, Aditum Bio, Advanced Technologies Solutions, Aequus Pharmaceuticals, AffyXell Therapeutics, Agilis Biotherapeutics, AgonOx, Aitbiotech, Aither Ingredient, Ajlan & Bros, AJNA BioSciences, Aker BioMarine, Aleafia Health, Allied Corp, Allogene Overland Biopharm, Allogene Therapeutics, Alloy Therapeutics, Alpha Tau Medical, Alpine Hemp Group, Altus Formulation, Amarantus BioSciences, Amgen, Amyris, Animalcare, Antoxerene, Apax Partners, Aphria, Apical Biotek, Apollo Therapeutics, Arbele, Arbutus, ARCH Personalized Medicine Initiative, Areteia Therapeutics, Aridis Pharmaceuticals, Arphio, Arrowhead Pharmaceuticals, Arthrosi Therapeutics, Aruvant Sciences, Arvinas, Ascendis Pharma, Asklepios Biopharmaceutical, Aslan Pharma, Astellas Pharma, AstraZeneca, ATAI Life Sciences, Athenex, ATMA Journey Centers, Atomwise, ATP, Atrapos Therapeutics, Atropos Therapeutics, Atvio Biotech, Aulos Bioscience, Auxly Cannabis Group, Avacta, Avactis Biosciences, Avalon GloboCare, Avaria Health & Beauty, Avvinity Therapeutics, Axis Therapeutics, Bain Capital, Bayer, Beckley Canopy Therapeutics, Beckley Foundation, Becton Dickinson, BeiGene, Beijing Genomics Institute (BGI), Berry Genomics, Betaliq, BevCanna, BHB Therapeutics, Bio-Me, Bio-Techne, BioAmber, BiocurePharm, Biohealth Innovation, Biolinear Technologies, BiolineRX, BioLite Japan, Biolojic Design, Biomedican, BioMed X Innovation Center, bioMerieux, BioMotiv, BioNanoSim, BioNova Pharmaceuticals, BioSymetrics, Blackstone, BLP Management, Blueberries Medical, Bluepha, BNS Ophthalmics, Boehringer Ingelheim, BostonGene, Breakthrough Diagnostics, BridgeBio Pharma, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Broadwing Bio, Buck Institute for Age Research, Bukwang Pharmaceuticals, Button Capital, Cancer Research Technology, Cannabics Pharmaceuticals, Cannabis Biocare, Cannabis Therapeutics, CannAmerica Brands, CannaRoyalty, Canopy Health Innovations, Capna Intellectual, Capnia, Casa Schmidt, Casebia Therapeutics, CB2 Therapeutics, CBDerma Technology, CBDistribution, CB Therapeutics, Celexor Bio, Celogics, Cena Life, Centauri Therapeutics, Centene, Centogene, Cerba Research, Cerevel Therapeutics, Cesca Therapeutics, Champions Oncology, Charlotte's Web, Chengdu Gaotong Isotope, China-Israel Biological Technology, China-Singapore Guangzhou Knowledge City, China Biotech Services, China National Biotech Group (CNBG), Chinese Future Industry Investment Fund, Chinook Therapeutics, ChromaDex, Cincinnati Children’s Hospital Medical Center, Cipla, CJ CheilJedang, Collagen Solutions Plc, Columbus Venture Partners, Consortium AI, Contour Therapeutics, Core One Labs, Cre8ive, CRISPR Therapeutics, CROMA Pharma, CureCell, Cure Therapeutics, Curi Bio, Cyclica, Cyclolab, CytoBioscience, Cytotheryx, Cytovant Sciences, Daewoong Pharmaceutical, Dance Biopharm, Deerfield Management, DemeRx, Demetra, Denka, Denka-KEW Genomics, Develco Pharma, Dizal Pharmaceutical, DolCas-Tenshi Bioceuticals, DolCas Biotech, Dona Blanca, Dongbao, Dragonfly Biosciences, Eastern Capital, Echo Investment Capital, Eclipse, Eden BioCell, Elanix Biotechnologies, Elevar Therapeutics, Eli Lilly, Emergence Therapeutics, Emory University, Entheogenix Biosciences, EpiPharma, ERS Genomics, Everads Therapy, Evero Health, Evotec, Excellmab, Exemplar Genetics, ExScientia, FairJourney Biologics, Fannin, FCM Global, Fedecore, Fedora Pharmaceuticals, FerGene, Ferring Pharmaceuticals, Filament Health, FJ Pharma, Flora Growth, FloVaria, Flow Pharma, Foresite Capital, FORMA Therapeutics, Fosun Pharmaceutical, FoxBio, Frazier Healthcare Ventures, Fresenius Kabi Pharmaceuticals, Frontage Laboratories, FSD Pharma, Fujitsu Laboratories, Full Spectrum Biosciences, Futura Medical, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, G3 Therapeutics, Galvani Bioelectronics, Gene Therapy Research Institution, Genevant Sciences, Geninus, Genome Institute of Singapore, Genomix Scientific, Genomma Lab Internacional, GeoVax, GHO Capital, Ginkgo BioWorks, Glaxo Group, GL Brands, GLG Pharma, Global Canna Labs, Global Drug Development Centre (GDCC) China, GNC, Golden Mountain Partners, Great Bay Bio, Grenco Science, Grow Biotech, Grunenthal, Grupo Curativa, GSK, GtreeBNT, Guangzhou Boji Medical Biotechnological, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Guangzhou Xiangxue Pharmaceutical, Hainan Sihuan Pharmaceutical, HaloVax, HealthBanks Biotech, Hefei Sageland Biotechnology, Heidelberg Pharma, HekaBio, Helomics, Henry Schein, Heritage Cannabis, Herman Holdings, Hi-Tech Pharmaceuticals, HiFiBio, HMNC Brain Health, Hollister Biosciences, Homology Medicines, Honor Epic Enterprises, Horizon Discovery, Horizon Pharma plc, Hoth Therapeutics, hVIVO, Hybrid Pharm, I-Bridge Capital, iBio, ICAN, Immorna, ImmuneCyte Life Sciences, ImmuneOncia Therapeutics, ImmunityBio, IMPACT Therapeutics, Imperial College London, Imutex, Indegene Lifesystems, India Colorada, Indivumed, Inmagene Biopharmaceuticals, Innovation Network Corporation, Insilico Biotechnology, Intercontinental Marketing, International Research Center on Cannabis and Mental Health, International Vitamin, Intuitive Surgical, Invictus MD Stategies, INVO Bioscience, IONTAS, IPS Specials, ITM Isotopen Technologien, Ix Therapeutics, JAGUAHR Therapeutics, Jaguar Health, Janssen Pharmaceuticals, Japan Industrial Partners, Japan Medical Isotope Technology Development, JCR Pharmaceuticals, Jeffs' Brands, Jeune, Jiangsu Recbio Technology, Johnson & Johnson, Johnson & Johnson Innovation, JRT Nurseries, Junshi Biosciences, Juvenescence, Juvenomics, Kadmon Pharmaceuticals, Kane Biotech, Kangmei Pharma, Keensight Capital, Kemwell BioPharma, Ketabon, KEW, Kings Group, Kinnate Biopharma, Kiromic Biopharma, Kishida Chemical, Kite Pharma, Knopp Biosciences, Kraig Biocraft Laboratories, Krystal Biotech, Kubota Pharmaceutical, Kurma Life Sciences Partners, Kyma Therapeutics, Kyowa Hakko Kirin, LabCentral, LeaderMed Health Group, Lenus Therapeutics, Lifera, Lifestyle Delivery Systems, LifeTech Scientific, Liht Cannabis, Lobe Sciences, Lonza, Lucidam, Lyndra Therapeutics, Maccura Biotechnology, Magdalena Biosciences, MAGiQ Therapeutics, Magnolia Extracts, Malaghan Institute, Mannin Research, MapKure, Maple Leaf Green World, Massachusetts General Hospital, MaSTherCell, Mawson Infrastructure, Mayo Clinic, Maze Therapeutics, McKesson, MD Anderson Cancer Center, Medcolcanna Organics, Medesole Healthcare and Trading, Medesole INVO Bioscience, Medical Food Solutions Research, Medipal Holdings, Medspray, Meiji Seika, Merck KGaA, Minerva Foods, MiNiSV, Mino Labs, MitoCareX Bio, Mitsui, Mizuho Capital, Molipharma, Molnlycke Health Care, Mota Ventures, MTP Material, Mundimed, Mycotopia Therapies, Mycrodose Therapeutics, Myovant Sciences, NacuGen Therapeutics, Napa Therapeutics, National Green Biomed, National Resilience, NEC, Neopharma, Neostell, Neovacs, Neptune Technologies & Bioressources, NeuroTheryX, NewCanna Hub, New York Genome Center (NYGC), Nexel, Nicox, Nikkol, NineteenGale Therapeutics, Nisarga Biotech, NLC Pharma, Noble Growth, Not-So-Gentle Tea Company, Novaliq, Nova Mentis Life Science, Novogene, Novo Nordisk, Nucleus RadioPharma, Nutra Manufacturing, Ocean Biomedical, OG Laboratories, OncoQuest, OncoStatyx, Oncotelic, OncoVent, Onegevity, One Small Planet, One World Pharma, Opiostop, OPKO Health, Optasia Medical, OptiBiotix, Oramed Pharmaceuticals, Oravax Medical, OrbiMed Asia Partners, Orgenesis, Overland ADCT BioPharma, Overland Pharmaceuticals, Oxford BioMedica, Oxford Biomedica Solutions, Oxford MEstar, Palantir, Panacea Biotech, Paragon Therapeutics, Peak Pharm Labs, PentixaPharm, PeptiAID, PeptiDream, Perennial, Pfizer, PharmaCielo, Phathom Pharmaceuticals, Phinest Cannabis, PhytoChem Technologies, Pillar Biosciences, Pittsburgh Life Sciences Greenhouse, Pivotal bioVenture Partners, Pivot Pharmaceuticals, Pleasure Peaks, Pluristem Therapeutics, Population Health Partners, Portage Glasgow, Portage Pharmaceuticals, Poseidon Innovation, Premas Biotech, Premier Biomedical, Prenetics, Priovant Therapeutics, Promethera Biosciences, Prometic Life Sciences, Provision Asia, PsyBioMed – Australia, Psyence Therapeutics, Pure Extracts Technologies, Pyxis Oncology, Qiagen, Q Therapeutics, Radiopharm Theranostics, Radiopharm Ventures, Rafarm, Rafarma Pharmaceuticals, RavenQuest BioMed, Recipharm, Refana, Regenacy Pharmaceuticals, Regencell Bioscience, Replay, ReproCell, Resmed, Resyca, Revive Therapeutics, Rochal Industries, Roche, Roivant Sciences, Rxilient Biotech, Samsung Bioepis, Sanofi, SanReno Therapeutics, Sansure Biotech, Sanuwave Health, SBI Capital Markets, Scailyte, Scintomics, SciSparc, Scohia Pharma, SEEK, SEngine Precision Medicine, Shanghai Chonghe Marine Industry, Shanghai Hi-Tech Nutraceuticals, Shenzhen Arimab Biopharmaceuticals, Shenzhen Hepalink Pharmaceutical, Shenzhen Neptunus Interlong Bio-Technique, Shenzhen Rhegen Biotechnology, Shenzhen Yunma Biotechnology, Singlera Genomics, Sinovant Sciences, SK Biopharmaceuticals, SkinBiotix, Skyline Medical, Smart Medicines GMP, Solaris, Soleno Therapeutics, Sorrento Therapeutics, Sorse Technology, Sosei, Southern Cross University, SpringWorks Therapeutics, Sproutly, Spydasilk Enterprises, Starbuds, Steep Hills Labs, Stellar Biotechnologies, STEM Animal Health, StillCanna, Strategic Vaccines, SunGen, Syena, Symbasis, Synlogic, Sysmex, Tactical Relief, TaiRx, TaiRx US, Takeda Pharmaceutical, Takenaka, Talem Therapeutics, Targetrin Therapeutics, Tauriga Sciences, TechCare, Tecres, Tenshi Kaizen, Tessa Therapeutics, Tetra Bio-Pharma, Thar Process, The Alchemists Kitchen, Theracell, Therapix Bio, ThermoGenesis, Thorne HealthTech, Thorne Research, Thousand Oaks Biopharmaceutical, Tikun Olam, TNK Therapeutics, Tnuva Group, Todos Medical, Tonghua Dongbao Pharma, Touchlight, TranScrip, Translational Medicine Accelerator, TriArm Therapeutics, TryptageniX, University College London, University of California, San Diego, University of Cambridge, University of Glasgow, University of Manchester, University of Oxford, Vaccines Lab SDN BHD, Vapium, Verde Leaf, Verily, Vertical Companies, ViaMune, Victa Biotherapeutics, Vifor Pharma, Viralgen, Virion Therapeutics, VISEN Pharmaceuticals, Visirna Therapeutics, VivaVision Biotech, Vivo Capital, Voltron Therapeutics, Vyaire Medical, Vyripharm, Walgreens, WardMM, Washington University in St Louis, Wheeler Bio, Wilson Wolf, World Class Extractions, WSG Group, Wuhan Rhecogen Biotechnology, WuXi Biologics, Wuxi STA, WuXi XDC, X-chem, Xcellomics, Xlife Sciences, Yissum Research Development, Yongyi Biotechnology, Yongyi Hi-Tech Nutraceuticals, Yuhan Corporation, YuYang DNU, Zhaotai Group, Zhejiang Jiuzhou Pharmaceutical, Ziopharm Oncology

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!